Home Newsfeeds Barclays Maintains Overweight on Immunogen, Raises Price Target to $9

Barclays Maintains Overweight on Immunogen, Raises Price Target to $9

Barclays analyst Peter Lawson maintains Immunogen (NASDAQ:IMGN) with a Overweight and raises the price target from $8 to $9.

byBenzinga Newsdesk

November 15, 2022

1 minute read

Barclays analyst Peter Lawson maintains Immunogen (NASDAQ:IMGN) with a Overweight and raises the price target from $8 to $9.

Tesla, ABB And Other Big Losers From Monday

By Lisa Levin

October 4, 5:00 AM

U.S. stocks closed sharply higher with the Dow Jones jumping more than 750 points on Monday. Here is the list of some big stocks recording losses in the previous session.

$APE

Top 5 Risk Off Stocks That Should Keep You Up At Night

By Lisa Levin

August 17, 8:54 AM

The most overbought stocks in the consumer staples sector presents an opportunity to go short on these overvalued companies.

CELH

8 Analysts Size Up Amazon’s Q1 Results, AWS Opportunity: ‘Likely The Biggest Winner In AI’

By Chris Katje

May 1, 1:28 PM

Amazon stock is seen as a winner by analysts after the Q1 results. Operating margins, AWS and the AI opportunity are highlighted as positives.

AMZN

AgEagle Aerial Systems Announces Effectiveness Of 1-For-20 Reverse Stock Split

By Benzinga Newsdesk

February 9, 9:11 AM

AgEagle Aerial Systems Inc. (NYSE:UAVS) (the "Company"), a leading provider of full stack drone, sensors and software solutions for customers worldwide in the commercial and government verticals, today announced that, on

UAVS

Barclays Maintains Overweight on Immunogen, Raises Price Target to $9

Related Posts

Tesla, ABB And Other Big Losers From Monday

Top 5 Risk Off Stocks That Should Keep You Up At Night

8 Analysts Size Up Amazon’s Q1 Results, AWS Opportunity: ‘Likely The Biggest Winner In AI’

AgEagle Aerial Systems Announces Effectiveness Of 1-For-20 Reverse Stock Split